The International Consortium on Lithium Genetics (ConLiGen): an initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment by Schulze Thomas G, Alda Martin, Adli Mazda, Akula Nirmala, Ardau Raffaella, Bui Elise T, Chillotti Caterina, Cichon Sven, Czerski Piotr, Del Zompo Maria, Detera-Wadleigh Sevilla D, Grof Paul, Gruber Oliver, Hashimoto Ryota, Hauser Joanna, Hoban Rebecca, Iwata Nakao, Kassem Layla, Kato Tadafumi, Kittel-Schneider Sarah, Kliwicki Sebastian, Kelsoe John R, Kusumi Ichiro, Laje Gonzalo, Leckband Susan G, Manchia Mirko, Macqueen Glenda, Masui Takuya, Ozaki Norio, Perlis Roy H, Pfennig Andrea, Piccardi Paola, Richardson Sara, Rouleau Guy, Reif Andreas, Rybakowski Janusz K, Sasse Johanna, Schumacher Johannes, Severino Giovanni, Smoller Jordan W, Squassina Alessio, Turecki Gustavo, Young L Trevor, Yoshikawa Takeo, Bauer Michael, McMahon Francis J in Neuropsychobiology (2010). PubMed

Abstract

For more than half a decade, lithium has been successfully used to treat bipolar disorder. Worldwide, it is considered the first-line mood stabilizer. Apart from its proven antimanic and prophylactic effects, considerable evidence also suggests an antisuicidal effect in affective disorders. Lithium is also effectively used to augment antidepressant drugs in the treatment of refractory major depressive episodes and prevent relapses in recurrent unipolar depression. In contrast to many psychiatric drugs, lithium has outlasted various pharmacotherapeutic 'fashions', and remains an indispensable element in contemporary psychopharmacology. Nevertheless, data from pharmacogenetic studies of lithium are comparatively sparse, and these studies are generally characterized by small sample sizes and varying definitions of response. Here, we present an international effort to elucidate the genetic underpinnings of lithium response in bipolar disorder. Following an initiative by the International Group for the Study of Lithium-Treated Patients (www.IGSLI.org) and the Unit on the Genetic Basis of Mood and Anxiety Disorders at the National Institute of Mental Health,lithium researchers from around the world have formed the Consortium on Lithium Genetics (www.ConLiGen.org) to establish the largest sample to date for genome-wide studies of lithium response in bipolar disorder, currently comprising more than 1,200 patients characterized for response to lithium treatment. A stringent phenotype definition of response is one of the hallmarks of this collaboration. ConLiGen invites all lithium researchers to join its efforts.

[ hide abstract ]

Discussed In Paper

Related In Paper

Variant Annotations

None.